Celiac Disease in Children
Conditions
Brief summary
To assess the adherence to gluten free diet by measuring faecal and urinary gluten immunogenic peptides (GIP). This will provide an objective measure for adherence.
Detailed description
The adherence to the GFD can be assessed through a dietary interview performed by a registered dietitian or patient self-reports, mucosal healing, assessed by a small bowel biopsy or CD serological screening tests showing decreasing levels of antibodies. However, none of these methods offer an accurate measure of dietary compliance. A novel method to monitor the adherence to the GFD by detection of immune-dominant gluten peptides in human faeces or urine using the anti-α -gliadin G12 antibody was described recently in the literature. Gluten peptides, in particular peptides equivalent to the immunogenic - α -gliadin-33-mer peptide, are resistant to gastrointestinal digestion and that ensures a significant amount of the ingested gluten is excreted in faeces. Consequently, recovery of detectable amounts of the immunogenic fraction in faeces or urine indicates that gluten has passed through the digestive tract, and in the case of urine was absorbed, and, therefore, that gluten has been consumed .
Interventions
DIAGNOSTIC_TESTdetecting Gluten peptides in faecal and urine samples
At each visit patient will: * Bring 4-day food diary (attached) * Fill symptoms and complaints questionnaire (attached) * Provide 24 h diet recall in case a food diary absents * Fill Biagi score questionnaire (attached) * Perform blood test of TTG * Provide stool and urine samples
Sponsors
Rabin Medical Center
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 17 Years
Inclusion criteria
* Age 2-17 years. * Either diagnosis of celiac disease or, in controls, no systemic disease or inflammation * For all groups parents will provide informed consent.
Exclusion criteria
° Children with suspected or known inflammatory bowel disease or other gastrointestinal or systemic diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between fecal gluten peptides and nutritional assessment for gluten free diet, and correlation with celiac serology. | one year | Our goal is to examine which method will be the most accurate, nutritional assessment or laboratory tests for the adherence to GFD |
Countries
Israel
Outcome results
None listed